ARCUTIS BIOTHERAPEUTICS, INC. Current Liabilities
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Current Liabilities of $160.34 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $160.34M.
- 2026-03-31: Liabilities, Current $163.20M.
- 2025-12-31: Liabilities, Current $129.84M.
- 2025-09-30: Liabilities, Current $99.77M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $160.34M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $163.20M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $129.84M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $99.77M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $103.94M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $91.13M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $81.01M 10-K · filed 2026-02-25 |
| 2024-09-30 | $172.43M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $51.35M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $47.31M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $46.67M 10-K · filed 2025-02-25 |
| 2023-09-30 | $41.89M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $36.66M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $37.02M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $37.81M 10-K · filed 2024-02-27 |
| 2022-09-30 | $37.10M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $27.48M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $32.96M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $33.33M 10-K · filed 2023-02-28 |
| 2021-09-30 | $19.06M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $13.35M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $15.31M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $22.60M 10-K · filed 2022-02-22 |
| 2020-09-30 | $21.15M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $19.28M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $12.22M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $5.24M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |